Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | FBP1 | P09467 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin Ag-1478 SCHEMBL31079458 | 1.00 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| Tyrphostin Ag-1478 SCHEMBL29483198 | 1.00 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| Tyrphostin Ag-1478 SCHEMBL29350062 | 1.00 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| Tyrphostin Ag-1478 SCHEMBL30362802 | 0.99 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| Tyrphostin Ag-1478 SCHEMBL5477838 | 0.99 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| Tyrphostin Ag-1478 SCHEMBL31466723 | 0.99 | EGFR (1.00) | EGFRKDM4EMAPTMAPK1FBP1 | |
| SCHEMBL21982440 | 0.94 | EGFR (0.89) | EGFRKDM4EMAPTMAPK1FBP1 | |
| SCHEMBL8258194 | 0.91 | EGFR (0.83) | EGFRKDM4EMAPTMAPK1FBP1 | |
| SCHEMBL18158234 | 0.91 | EGFR (0.83) | EGFRKDM4EMAPTMAPK1FBP1 | |
| SCHEMBL1417950 | 0.90 | EGFR (0.82) | EGFRKDM4EMAPTMAPK1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2968 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| US-20250319110-A1 | SURFACE CALR CHEMICAL INDUCERS | ZON LEONARD (US) | 2025-10-16 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250242043-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | LIGACHEM BIOSCIENCES, INC. (KR) | 2025-07-31 | — | — | US | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| US-20020156023-A1 | Lometrexol combination therapy | TULARIK INC. | 2002-10-24 | — | — | US | claimed |
| WO-2002045717-A1 | LOMETREXOL COMBINATION THERAPY | TULARIK INC. (US) | 2002-06-13 | — | — | WO | claimed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | claimed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | claimed |
| US-6004967-A | TOPICALLY ADMINISTERING 4-(3-BROMOPHENYLAMINO)-6,7-DIMETHOXYQUINAZOLINE TO TREAT HYPERPROLIFERATION CAUSED BY PAPILLOMAVIRUS INFECTION | SUGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |